Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab

Abstract Immune dysregulation is a hallmark of chronic lymphocytic leukemia (CLL). Anti‐CD20 antibodies (e.g., rituximab [R]) can be combined with venetoclax (Ven) to treat CLL. However, anti‐CD20 antibodies can increase hypogammaglobulinemia risk, while the effects of Ven on immune dysregulation ar...

全面介紹

書目詳細資料

發表在:	HemaSphere
Main Authors:	Arnon P. Kater, Barbara F. Eichhorst, Carolyn J. Owen, Ulrich Jaeger, Brenda Chyla, Marcus Lefebure, Rosemary Millen, Yanwen Jiang, Maria Thadani‐Mulero, Michelle Boyer, John F. Seymour
格式:	Article
語言:	英语
出版:	Wiley 2024-08-01
在線閱讀:	https://doi.org/10.1002/hem3.146